---
document_datetime: 2023-09-21 17:13:46
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/scientific-conclusion/xenical-h-c-154-psu-17-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf
document_name: xenical-h-c-154-psu-17-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf
version: success
processing_time: 0.7760887
conversion_datetime: 2025-12-23 00:32:31.457671
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

25 April 2013 EMA/CHMP/256042/2013 Committee for Medicinal Products for Human Use (CHMP)

## Xenical orlistat

Procedure no. EMEA/H/C/000154/PSU/0017

Scientific conclusions and grounds recommending the variation to the terms of the Marketing Authorisation

●

7 Westferry Circus

Canary Wharf

●

London E14 4HB

+44 (0)20 7418 8400

Facsimile

●

United Kingdom

+44 (0)20 7418 8416

Website

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for Xenical, the scientific conclusions of PRAC are as follows:

In view of available data regarding orlistat, the PRAC considered that changes to the product information were warranted (see below).

Update of section 4.4 of the SmPC to provide clearer information regarding renal toxicity and in section 4.8 to provide updated clarification on renal and hepatic toxicities

Update  of  section  4.5  of  the  SmPC  to  add  information  regarding  interactions  with  antidepressant, antipsychotics and Lithium.

The Package leaflet is also updated accordingly.

The CHMP agrees with the scientific conclusions made by the PRAC.

## Grounds recommending the variation to the terms of the Marketing Authorisation

On the basis of the scientific conclusions for Xenical the CHMP is of the opinion that the benefit-risk balance of the medicinal product containing the active substance orlistat is favourable subject to the proposed changes to the product information.

The CHMP recommends that the terms of the Marketing Authorisation should be varied.